Michels, Monique http://orcid.org/0000-0001-8440-1976
Jesus, Gabriel Fernandes Alves
Voytena, Ana Paula Lorenzen http://orcid.org/0000-0002-4411-5526
Rossetto, Marina http://orcid.org/0000-0001-9410-3083
Ramlov, Fernanda http://orcid.org/0000-0001-7925-3980
Córneo, Emily http://orcid.org/0000-0003-4250-6635
Feuser, Paulo http://orcid.org/0000-0003-2372-8945
Gelain, Daniel http://orcid.org/0000-0001-5254-0509
Dal-Pizzol, Felipe http://orcid.org/0000-0003-3003-8977
Funding for this research was provided by:
UNESC
GABBIA
Article History
Received: 4 March 2021
Accepted: 11 October 2021
First Online: 14 December 2021
Declarations
:
: Gabbia Biotechnology is developing paraprobiotics for the commercial purposes. Gabriel Jesus, Marina Rosseto, and Ana Paula Voytena are members of Gabbia Biotechnology. The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
: We confirm that the manuscript has been read and approved by all named authors and that there are no other persons who satisfied the criteria for authorship, but are not listed. We further confirm that the order of authors listed in the manuscript has been approved by all of us.
: Data will be made available on reasonable request.